Teva
Teva Pharmaceutical Industries Ltd., commonly known as Teva, is a leading global pharmaceutical company headquartered in the United States. Founded in 1901, Teva has established a strong presence in over 60 countries, with significant operations in Europe, North America, and Israel. The company primarily focuses on generic and specialty pharmaceuticals, offering a diverse portfolio that includes innovative treatments for various medical conditions. Teva is renowned for its extensive range of generic medications, which provide affordable alternatives to brand-name drugs, making healthcare more accessible. The company has achieved notable milestones, including being one of the largest generic drug manufacturers worldwide. With a commitment to quality and sustainability, Teva continues to enhance its market position through strategic acquisitions and a robust pipeline of new products, solidifying its reputation as a key player in the pharmaceutical industry.
DitchCarbon Score
How does Teva's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Other Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Teva's score of 8 is higher than 72% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Teva's reported carbon emissions
In 2022, Teva's carbon emissions totalled approximately 498,641,000 kg CO2e for Scope 1 and 498,641,000 kg CO2e for Scope 2. The company has not disclosed any Scope 3 emissions for this year. Over the years, Teva has shown a trend of reducing its emissions, with a notable decrease from 656,646,000 kg CO2e in 2019 to 572,121,000 kg CO2e in 2021 for Scope 1 and 2 emissions combined. Teva's emissions data from previous years indicates a commitment to reducing its carbon footprint, with Scope 1 emissions decreasing from 656,646,000 kg CO2e in 2019 to 572,121,000 kg CO2e in 2021. However, the company has not set specific reduction targets or initiatives as part of its climate commitments, nor has it engaged with the Science Based Targets initiative (SBTi) for formal reduction targets. Overall, while Teva has made progress in reducing its emissions, the absence of defined reduction targets suggests a need for more structured climate commitments moving forward.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 392,268,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 455,017,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | 847,285,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Teva is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
